Physician profile
John E Reuter
NPI 1861518177
$3,813.40
in general payments reported to CMS, 2019-2025
34 companies · $417 in 2025
The $417 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $360 · 2021: $285 · 2022: $713 · 2023: $541 · 2024: $799 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,084.35 | 2019-2025 | Jot Dx, Xience Skypoint, Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $424.40 | 2019-2024 | Repatha |
| Medtronic, INC. | $217.20 | 2022-2025 | Cg Future, Corevalve Evolut R |
| Pfizer INC. | $182.52 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $181.09 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $162.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $155.59 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $152.76 | 2019-2025 | Farxiga |
| Kiniksa Pharmaceuticals International, Plc | $106.35 | 2024 | Arcalyst |
| Novo Nordisk INC | $101.33 | 2023-2024 | Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.48 | 2019-2025 | Lifevest |
| Abiomed | $97.75 | 2025 | |
| Heartflow, INC. | $96.13 | 2023-2025 | Ffrct |
| Cvrx, INC. | $92.36 | 2023-2024 | Barostim Neo System |
| Edwards Lifesciences Corporation | $62.68 | 2025 | Sapien 3 Ultra Resilia |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Reuter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.